PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

PTC Ther­a­peu­tics is stay­ing busy ahead of the Thanks­giv­ing hol­i­day.

On Tues­day af­ter­noon, the com­pa­ny an­nounced that a Phase 2 tri­al eval­u­at­ing its ex­per­i­men­tal ALS …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER